AI Summary
A new compound called (R)-9k has been developed and tested as a potential treatment for colorectal cancer. It showed stronger anti-proliferative activity than current chemotherapy drugs and had fewer adverse reactions. (R)-9k works by inhibiting tubulin polymerization, and it appears to be a promising treatment option for colorectal cancer.
In view of the serious adverse reactions and clinical toxicity of first line therapy 5-Fluorouracil and lack of small molecule therapeutics in colorectal cancer chemotherapy, a series of natural scaffold-based 3-arylindanone derivatives (9a-q) were designed, synthesized and evaluated as tubulin polymerization inhibitors targeting colchicine site. The most potent colchicine binding site inhibitor (CBSI), (R)-9k, possessed 14-38 times dominant anti-proliferative activity against three colon cancer cell lines than 5-Fluorouracil. Particularly, (R)-9k showed higher selectivity against human normal cells compared with 5-Fluorouracil and colchicine, and displayed negligible cardiotoxicity through hERG assessment. Furthermore, the binding of (R)-9k to the colchicine site was strongly supported by EBI competition assay and (R)-9k inhibited more tubulin polymerization than colchicine. Besides, the mechanism of action and binding modes of (R)-9k were verified by molecular dynamics simulations and docking. Therefore, (R)-9k could be regarded as a promising CBSI for colorectal cancer therapy.
You have access to this article
Please wait while we load your content… Something went wrong. Try again?